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Abstract 
Background: Artemisinin‑based therapy is the current standard treatment for non‑severe malaria due to Plasmo-
dium falciparum. The potential for asymptomatic liver toxicity of this therapy and its implication in clinical practice is 
currently unknown. The aim of this study is to assess the hepatic function in patients treated with a standard three‑
day artemisinin‑based regimen and to compare it with the quinine‑doxycycline regimen.
Methods: Retrospective and comparative study of returned adult travellers admitted with non‑severe P. falciparum 
malaria. Fifty‑seven patients were included: 19 treated with artemisinin‑based therapy and 38 with quinine‑doxycy‑
cline therapy.
Results: During treatment, when compared with quinine‑doxycycline group, the artemisinin‑lumefantrine group 
presented a higher proportion of significant liver enzyme abnormalities (42 vs. 5%, p < 0.01) and a higher peak value 
of aspartate aminotransferase (131 vs. 64 U/L, p < 0.01) and alanine aminotransferase (99 vs. 75 U/L, p = 0.05). None of 
the patients was symptomatic, there were no treatment interruptions and all patients achieved clinical cure.
Conclusions: Treatment of uncomplicated falciparum malaria with artemisinin‑based therapy might cause asympto‑
matic liver enzyme abnormalities in the first days of treatment. Nevertheless, these liver enzyme abnormalities seem 
to be harmless, asymptomatic and self‑limited.
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Background
Artemisinin based combination therapy (ACT) is the 
current standard treatment for uncomplicated malaria 
caused by Plasmodium falciparum [1]. Owing to their 
rapid onset of action and quick elimination, artemisinin 
derivatives are very effective in reducing parasite load 
and have favourable safety and tolerability profiles [2, 3]. 
In Portugal, artemether/lumefantrine fixed dose combi-
nation (AL), currently the only available ACT, came into 
medical use in 2013 and is an alternative to quinine plus 
doxycycline (QD), the previous first-line regimen [1]. The 
main reasons for this paradigm change are the safety and 
tolerability profiles of AL and the remaining ACT regi-
mens compared to QD [3, 4].
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Hepatotoxicity associated with ACT has been 
described in animal models [5–7] and several series in 
humans have shown elevation of liver enzymes of unde-
termined clinical significance [8]. On the other hand, it 
has rarely been described for QD [9–11] and AL regi-
mens [12]. Even pooled analysis of randomized con-
trolled trials with AL did not find significant hepatic 
toxicity. However, the laboratory analysis was performed 
only at baseline and on day 28 the AL effect in the acute 
phase was not tested [13].
The potential for asymptomatic liver toxicity and its 
implication in clinical practice need clarification in order 
to understand the possible impact of ACT on a wider 
scale. It is also important to assess whether transami-
nase elevation seen during ACT can be explained solely 
by malaria-associated liver damage or if it is more likely 
associated with drug toxicity. It is important to take into 
account that most ACT for malaria treatment takes place 
in low-resource settings, where routine toxicity monitor-
ing might not be feasible.
The aim of this study is to assess the hepatic function in 
patients hospitalized with non-severe falciparum malaria 
treated with a standard three-day regimen of AL, and to 
compare them with a historical cohort of patients admit-
ted for the same reason and treated with a QD regimen.
Methods
A retrospective, comparative study was performed, 
including adult patients (over 18  years old) admitted 
to the Infectious Diseases Ward of Centro Hospitalar 
de São João, Porto, Portugal with the diagnosis of non-
severe falciparum malaria (as defined by the World 
Health Organization [1]). The diagnosis of malaria 
was based on rapid diagnostic test (BINAX Malaria 
Now®) and microscopy (thin blood film; parasitaemia is 
expressed as % of parasitized red blood cells). The liver 
function tests were performed with COBAS® and the 
same technique was used in both groups [kinetic enzyme 
essay for transaminases and colorimetric enzyme essay 
for bilirubin, gamma-glutamyl transferase (GGT) and 
alkaline phosphatase (AP)]. Patients were identified 
patients using the hospital database (IEG-HSJ®) and 
subsequently clinical records were consulted. Data con-
cerning demography (gender, age, nationality), past 
medical history, country of malaria acquisition, dura-
tion of symptoms, date of travel to Portugal, duration of 
hospitalization, duration of symptoms after beginning 
of treatment, co-infections, level of parasitaemia and 
its trend, level of liver enzymes before treatment and 
its highest value, coagulation times, symptoms of liver 
dysfunction (asthaenia, nausea, vomiting, icterus) and 
death was collected. The aim was to compare the liver 
dysfunction in patients hospitalized with non-severe 
falciparum malaria treated either with AL or QD. Two 
groups of patients were created according to the treat-
ment received: those treated with AL (all patients admit-
ted during 2014) and those treated with QD per os (all 
patients admitted between 2010 and 2013), with an AL: 
QD ratio of 1: 2. The primary outcome was significant 
liver enzyme abnormalities (defined as an elevation of 
trasaminases more than five times the normal upper 
limit in asymptomatic patients or three times in symp-
tomatic patients; elevation of total bilirubin or AP more 
than two times the normal upper limit). The secondary 
outcomes were malaria cure, treatment interruption due 
to side effects and normalization of liver enzymes on 
follow-up. The most appropriate measure of central ten-
dency and distribution for variables description (mean 
and standard deviation if normal distribution or median 
and interquartile range if non-normal distribution) was 
used. The two groups were compared using the most 
suitable statistical test; statistical analysis was performed 
with SPSS 22.0® and a two-sided p value <0.05 was con-
sidered statistically significant.
The protocol was approved by the Centro Hospitalar 
São João Ethics Committee.
Results
A total of 57 patients was included: 19 treated with AL 
and 38 with QD. The main epidemiological, clinical and 
analytical variables considered are shown in Table  1, 
including the comparison of the two groups. There were 
no statistically significant differences between the two 
groups regarding the proportion of males or the mean 
age (p  =  0.65 and p  =  0.48, respectively). The major-
ity of patients were Portuguese and acquired malaria in 
Angola; 49.3% had a previous episode of malaria. None 
of the patients reported previous hepatic disease or anti-
malarial prophylaxis use.
The initial parasitaemia was significantly higher in the 
QD group (median 1.0 vs. 0.5; p = 0.03, Mann–Whitney 
U test). There was no difference in the number of days 
until symptom resolution, although the number of days 
until parasitaemia clearance was higher in the QD group 
(but not statistically significant, p = 0.09).
Other infectious causes of liver dysfunction were 
excluded.
At diagnosis, there were no differences between the 
groups considering the levels of aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), GGT, AP, 
total bilirubin or activated partial thromboplastin time 
(aPTT). However, during treatment, the AL treatment 
group presented a higher proportion of patients with 
significant liver enzyme abnormalities [8/19 (42%) vs. 
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2/38 (5%); p < 0.01] and a higher peak value of AST and 
ALT (p  <  0.01 and p =  0.05, respectively). The remain-
ing liver panel was not significantly different between 
the groups. None of the patients was symptomatic and 
there were no treatment interruptions. In the AL-treated 
group, the duration of hospitalization was not prolonged 
in those with hepatic dysfunction (median: 5.5 vs. 4 days; 
p = 0.06, Mann–Whitney U test). All patients were dis-
charged with clinical and microbiological evidence of 
cure; the mean duration of hospitalization was 5.6 days. 
AST and ALT returned to normal during outpatient fol-
low-up in all cases.
Table 1 Main epidemiological, clinical and analytical variables comparing the two treatment groups: artemether–lume-
fantrine (AL) and quinine-doxycycline (QD)
Bold indicates significant values at p ≤ 0.05
a Pearson Chi square
b Independent t test
c Fisher’s exact test
d Mann–Whitney U test









 Male gender (n, %) 51 (89%) 18 (95%) 33 (87%) 0.65a
 Age (mean in years, SD) 41.2 (9.7%) 40 (10) 42 (10) 0.63b
 Portuguese nationality (n, %) 49 (86%) 18 (95%) 31 (81%) 0.25c
Country of malaria acquisition 0.48c
 Angola (n, %) 37 (65%) 11 (58%) 26 (68%)
 Mozambique (n, %) 7 (12.3%) 2 (11%) 5 (13%)
 Other (n, %) 13 (22.8%) 6 (31.6) 7 (18.4%)
 Past history of malaria (n, %) 23 (49.3%) 5 (26%) 18 (47%) 0.16c
Parasitaemia
 Initial parasitaemia (n, %) (median, IQR) 1.0 (1.5) 0.5 (0.9) 1.0 (1.5) 0.03d
 Days until symptoms resolution (median, IQR) 2 (2) 2 (1) 2 (2) 0.89d
 Days until no parasitaemia (median, IQR) 2 (2) 2 (2) 3 (3) 0.09d
Liver panele
 At diagnosis
  Initial AST (median, IQR) 44 (29.5) 46 (41) 42 (26) 0.99d
  Initial ALT (median,IQR) 41 (52) 32 (52) 44 (53) 0.50d
  Initial GGT (median, IQR) 51 (91) 48 (100) 52 (87) 0.84d
  Initial AP (median, IQR) 67 (32.5) 77 (32) 60 (30) 0.13d
  Initial total bilirubin (median, IQR) 1.2 (0.7) 1.2 (0.7) 1.2 (0.7) 0.53d
  Initial aPTT (median, IQR) 34.8 (5.9) 33 (5) 34 (7) 0.45d
During treatment
 Highest AST (median, IQR) 64 (83) 131 (278) 58 (50) <0.01d
  Number of days until highest value (median, IQR) 2 (4) 3 (3) 1 (5) 0.43d
 Highest ALT (median, IQR) 83 (88.5) 99 (297) 75 (72) 0.05d
  Number of days until highest value (median, IQR) 3 (4) 3 (2) 2.5 (4) 0.77d
 Highest GGT (median, IQR) 72.5 (108) 93 (160) 66 (99) 0.16d
 Highest AP (median, IQR) 71 (30) 84 (63) 70 (31) 0.07d
 Highest total bilirubin (median, IQR) 1.6 (1.3) 1.6 (1.4) 1.5 (1.3) 0.85d
 Highest aPTT (median, IQR) 34.8 (6.2) 38 (6) 34 (5) 0.06d
Outcomes
 Asymptomatic liver dysfunction (n, %) 10 (17.5%) 8 (42%) 2 (5%) <0.01c
 Symptomatic liver dysfunction (n,%) 0 0 0 –
 Death (n, %) 0 0 0 –
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Discussion
In this study, it is reported for the first time the asso-
ciation between AL treatment in non-severe falcipa-
rum malaria and liver enzyme abnormalities occurring 
on the first day of treatment (which was not observed 
in the QD group). Treatment of uncomplicated malaria 
caused by Plasmodium falciparum with ACT has high 
success rates and low described toxicities [13]. However, 
as for most diseases of the underdeveloped world, post-
marketing surveillance is scarce, especially for non-fatal 
complications.
When AL treatment became the standard treatment in 
Centro Hospitalar São João, a new trend towards an eleva-
tion of hepatic transaminases was noted that could raise 
questions about AL treatment safety. Nevertheless, these 
results do not support this view, as significantly higher 
ALT and AST observed in patients treated with AL were 
not accompanied by symptoms or complications related to 
hepatic dysfunction and did not delay hospital discharge.
Hepatic (elevation of AST, ALT and GGT; liver cells 
degeneration on histology), cardiac, renal, and neurotox-
icity, as well as embryonic malformations, associated with 
ACT regimens have been described in animal models [5–
7, 14]. However, these have not been shown to be relevant 
in widespread clinical use in humans. This discrepancy 
in toxicity between human and animal studies is thought 
to be explained by pharmacokinetic properties of arte-
misinins. Toxicity seems to be associated mostly with drug 
exposure (i.e., the area under the drug concentration–time 
curve). Intramuscular administration of artemisinins, 
mostly used in animal experiments, seems to be associated 
with delayed drug release and is thus more prone to toxic-
ity, as opposed to oral administration used to treat human 
disease, which seems to be generally safe [15, 16].
In the setting of no previous hepatic disease (as in this 
study), hepatic dysfunction in the context of non-severe 
malaria can either be due to the disease or to drug tox-
icity. The only statistically significant difference between 
the groups (AL vs. QD) regarding general characteristics 
and disease presentation was the level of parasitaemia, 
which was significantly higher in the QD group. As such, 
in this study, hepatic dysfunction caused by malaria does 
not seem a plausible explanation. On the other hand, 
there is no data assessing hepatic toxicity during the first 
days of treatment [13]. Liver damage associated with 
ACT seems to arise from the release of reactive oxygen 
species and oxidative stress resultant from their strong 
parasitical activity, with this abrupt and marked change 
in oxidative status having the potential of damaging liver 
cells by decreasing the hepatic glutathione S-transferase 
levels and the superoxide dismutase and catalase activi-
ties [17, 18]. However, for the vast majority of patients 
in all reviews and citations, as well as for all patients 
included in this comparative study, these alterations are 
quite benign and always transient, most likely translat-
ing a physiological, short-term, hepatic adaptation to 
artemisinin derivatives rather than true toxicity [13, 19]. 
On the other hand, the onset of action between QD and 
AL is known to be different [1, 20]: the latter combina-
tion has a quicker onset of action, with a higher per cent 
of parasite killing (and hence a quicker drop in the level 
of parasitaemia). The authors question if this faster para-
site killing, with consequent higher load for clearance by 
the reticuloendothelial system, would explain self-limited 
liver enzyme abnormalities.
The main limitation of this study, regarding its purpose, 
is that it is not a randomized controlled trial. Because 
this were carried out prior to the introduction of ACT in 
clinical practice in Portugal, the switch from QD to AL 
was automatic when the regimen was available. The dif-
ferences between QD and AL were suspected with the 
continued use of the latter. However, previous studies 
were not designed to find a difference, as described in 
this study.
This study is a small, retrospective, observational study 
and therefore selection bias might exist: the QD-treated 
patients were selected in 2010–2013 and the AL-treated 
patients in 2014. However, the migration pattern to Por-
tugal did not change during the study period (2010–2014) 
and the baseline demographic and analytic characteris-
tics did not differ between the groups.
Conclusions
Treatment of uncomplicated falciparum malaria with AL 
might cause asymptomatic liver enzyme abnormalities 
in the first days of treatment. However, the liver enzyme 
abnormalities seem to be harmless, asymptomatic and 
self-limited, not affecting clinical outcome. As such, this 
should not discourage the use of this treatment, but clini-
cians should be aware of this potential effect in order not 
to overestimate or undervalue it.
Authors’ contributions
A‑SP: data collection, data analysis, writing of manuscript; RR, FA, RD: data 
collection, writing and approval of manuscript; ASi: writing and approval of 
manuscript; CA: coordination, approval of manuscript; ASa: coordination. All 
authors read and approved the final manuscript.
Competing interests
The authors have declared that they have no competing interests.
Availability of data and materials
The data are available through the corresponding author.
Consent for publication
The authors consent for publication.
Ethics approval and consent to participate
The protocol was submitted to the Ethics Committee of Centro Hospitalar São 
João and approval was obtained.
Page 5 of 5Silva‑Pinto et al. Malar J  (2017) 16:43 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Received: 1 September 2016   Accepted: 17 January 2017
References
 1. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World 
Health Organization; 2015.
 2. WHO. Antimalarial drug combination therapy. Report of a WHO Technical 
Consultation. World Health Organization, 2001.
 3. McIntosh HM, Olliaro P. Artemisinin derivatives for treating severe malaria. 
Cochrane Database Syst Rev. 2000;(2):CD000527.
 4. Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, et al. 
Quinine, an old anti‑malarial drug in a modern world: role in the treat‑
ment of malaria. Malar J. 2011;10:144.
 5. Omotuyi IO, Nwangwu SC, Okugbo OT, Okoye OT, Ojieh GC, Wogu DM. 
Hepatotoxic and hemolytic effects of acute exposure of rats to artesunate 
overdose. Afr J Biochem Res. 2008;2:107–10.
 6. Owumi SE, Gbadegesin MA, Odunola OA, Adegoke AM, Uwaifo AO. Toxic‑
ity associated with repeated administration of artemether–lumefantrine 
in rats. Environ Toxicol. 2015;30:301–7.
 7. Yin JY, Wang HM, Wang QJ, Dong YS, Han G, Guan YB, et al. Subchronic 
toxicological study of two artemisinin derivatives in dogs. PLoS One. 
2014;9:e94034.
 8. Ribeiro IR, Olliaro P. Safety of artemisinin and its derivatives: a review of 
published and unpublished clinical trials. Med Trop (Mars). 1998;58:50–3.
 9. Farver DK, Lavin MN. Quinine‑induced hepatotoxicity. Ann Pharmacother. 
1999;33:32–4.
 10. Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or 
doxycycline and hepatotoxicity: a population based case‑control study. J 
Clin Pharm Ther. 2007;32:483–7.
 11. Punukollu RC, Kumar S, Mullen KD. Quinine hepatotoxicity. An under‑
recognized or rare phenomenon? Arch Intern Med. 1990;150:1112–3.
 12. Bakshi R, Hermeling‑Fritz I, Gathmann I, Alteri E. An integrated assess‑
ment of the clinical safety of artemether–lumefantrine: a new oral 
fixed‑dose combination antimalarial drug. Trans R Soc Trop Med Hyg. 
2000;94:419–24.
 13. Makanga M, Bassat Q, Falade CO, Premji ZG, Krudsood S, Hunt P, et al. 
Efficacy and safety of artemether–lumefantrine in the treatment of acute, 
uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J 
Trop Med Hyg. 2011;85:793–804.
 14. Angus B. Novel anti‑malarial combinations and their toxicity. Expert Rev 
Clin Pharmacol. 2014;7:299–316.
 15. Efferth T, Kaina B. Toxicity of the antimalarial artemisinin and its derva‑
tives. Crit Rev Toxicol. 2010;40:405–21.
 16. Gordi T, Lepist EI. Artemisinin derivatives: toxic for laboratory animals, safe 
for humans? Toxicol Lett. 2004;147:99–107.
 17. Adaramoye OA, Osaimoje DO, Akinsanya AM, Nneji CM, Fafunso MA, 
Ademowo OG. Changes in antioxidant status and biochemical indices 
after acute administration of artemether, artemether–lumefantrine and 
halofantrine in rats. Basic Clin Pharmacol Toxicol. 2008;102:412–8.
 18. Cui L, Su XZ. Discovery, mechanisms of action and combination therapy 
of artemisinin. Expert Rev Anti Infect Ther. 2009;7:999–1013.
 19. Kurth F, Belard S, Basra A, Ramharter M. Pyronaridine‑artesunate 
combination therapy for the treatment of malaria. Curr Opin Infect Dis. 
2011;24:564–9.
 20. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N, et al. Artesu‑
nate combinations for treatment of malaria: meta‑analysis. Lancet. 
2004;363:9–17.
